Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

NCT01611623 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Esanex Inc.